1. Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy
   Mao Qixing et al, 2015, Medicine CrossRef
2. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
   Miso Kim et al, 2015, PLOS ONE CrossRef
3. Emerging concepts on drug resistance in bladder cancer: Implications for future strategies
   Francesco Massari et al, 2015, Critical Reviews in Oncology/Hematology CrossRef
4. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I–II trials
   Orazio Caffo et al, 2016, Radiotherapy and Oncology CrossRef
5. Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine‐containing combination chemotherapy
   Nagahide Matsumura et al, 2017, International Journal of Urology CrossRef
6. RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
   Zhenxing Yang et al, 2019, BMC Urology CrossRef
7. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
   Xia Zhang et al, 2021, International Journal of Molecular Sciences CrossRef
8. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy
   Tobias Klatte et al, 2015, Journal of Urology CrossRef
9. Clinical Perspectives of ERCC1 in Bladder Cancer
   Konstantinos Koutsoukos et al, 2020, International Journal of Molecular Sciences CrossRef